Coave Therapeutics to Present at Upcoming Conferences

27 Mar 2024
www.globenewswire.com
Gene Therapy
Coave Therapeutics to Present at Upcoming Conferences
Paris, France, March 27, 2024 – Coave Therapeutics (‘Coave’), a genetic medicine company focused on developing life-changing therapies, announces that its management will be attending the following upcoming investor and industry conferences:
Cell & Gene Meeting on the Med – April 9-11 ; Rome, Italy
Company Presentation by CEO Rodolphe Clerval on April 10 at 13.45 CET
LSX World Congress – April 29-30 ; London, UK
CEO Rodolphe Clerval attending and available for investor meetings
BioEquity Europe – May 12-24 ; San Sebastián, Spain
Company Presentation by CEO Rodolphe Clerval - Date/Time TBC
Gene Therapy Analytical Development Europe Summit - May 22-24 ; London, UK
Presentation by COO Patricia Françon on May 24 at 10.00 BST
In addition, Coave’s scientific team will be present at the upcoming scientific, medical & regulatory conferences:
ARVO (Association for Research in Vision and Ophthalmology) - May 5-6 ; Seattle, WA, US
ASGCT (American Society of Gene and Cell Therapy) - May 7-11 ; Baltimore, MD, US
***
At Coave Therapeutics, we are leading the transition of genetic medicine from rare to prevalent conditions, starting with neurodegenerative and eye diseases. Our proprietary ALIGATER™ (Advanced Vectors-Ligand Conjugates) platform introduces chemical modifications onto AAV capsids or Lipid Nanoparticles (LNPs) to overcome the limitations of current vectors on efficacy, safety, and manufacturability.
With low doses and optimized routes of administration, our conjugated vectors have demonstrated markedly improved transduction and biodistribution in the central nervous system and the eye across different species. Our diverse pipeline of novel genetic medicines can potentially transform the lives of people afflicted by rare and prevalent neurodegenerative and ocular diseases – including genetically and non-genetically defined indications.
Headquartered in Paris, France, Coave Therapeutics is backed by leading international life sciences investors. For more information about the science, pipeline, and people, please visit https://coavetx.com/ and follow us on LinkedIn.
CONTACTS
Rodolphe Clerval, CEO
contact@coavetx.com
MEDiSTRAVA
Sylvie Berrebi, Leila Adlam, Mark Swallow
coavetx@medistrava.com
Tel: +44 (0)203 928 6900


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.